Search results for: Market Access

OHE’s submission for the DHSC’s next 10 years of planning

9 December 2024

…enable access for harder to reach groups or those where face-to-face services are a barrier to access? Where would increased use of technology exacerbate these inequalities for those who with…

Privacy Policy

…from being accidentally lost, used or accessed in an unauthorised way, altered or disclosed. In addition, we limit access to your personal data to those employees, agents and contractors and…

Future Cases of Dementia among People Born in 2015 & the Dementia Drug Pipeline

6 October 2015

…to the marketed treatments. In fact only one marketed disease modifying drug was identified; idebenone. This drug is marketed for treatment of cognitive defect within a relatively small range of…

OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development

2 August 2016

…and Equity from Office of Health Economics   Modelling the Value of Early Access Schemes and Adaptive Pathway Approaches by Mikel Burdud A range of early access agreements and adaptive…

Medicine

…and consumption. Balancing these interests within a healthcare system is crucial to promote accessibility, affordability, and innovation in medicines, maximizing their positive impacts on public health. The rising expenditure on…

The changing role of the NHS over time

14 August 2023

…Term Plan. [online] Available at: https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pd f [Accessed 16 Jun. 2023]. Office for National Statistics, 2017. Causes of death over 100 years. [online] Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/causesofdeathover100years/2017-09-18 [Accessed 10 Aug. 2023]….

How Restrictive are NICE ‘Optimised’ Decisions?

27 April 2023

…‘Optimised’ Decisions: What is the Recommended Level of Patient Access?. OHE Contract Research. Available from https://www.ohe.org/publications/nice-optimised-decisions-what-recommended-level-patient-access/ O’Neill P, Devlin NJ. (2010). An analysis of NICE’s ‘restricted’ (or ‘optimized’) decisions. Pharmacoeconomics…

An eye on sustainability at the Economist’s Future of Health Europe

30 October 2023

…adopt eco-friendly transport methods by providing safe bike locks and accessible bike clinics. When considering the interconnectivity of health and climate change, there is real value in organisational transformation and…

Drugs and Vaccines for Developing Countries

1 June 2011

…for some global disease products. Economic growth in some emerging market countries increases the attractiveness of those markets for some MNCs, which are exploring innovative strategies to expand sales and…